Chapter 1. NEURODEGENERATIVE DISEASES DRUGS MARKET – Scope & Methodology

1.1. Market Segmentation

1.2. Assumptions

1.3. Research Methodology

1.4. Primary Sources

1.5. Secondary Sources

Chapter 2. NEURODEGENERATIVE DISEASES DRUGS MARKET – Executive Summary

2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)

2.2. Key Trends & Insights  

2.3. COVID-19 Impact Analysis

      2.3.1. Impact during 2023 – 2030

      2.3.2. Impact on Supply – Demand

Chapter 3. NEURODEGENERATIVE DISEASES DRUGS MARKET – Competition Scenario

3.1. Market Share Analysis

3.2. Product Benchmarking

3.3. Competitive Strategy & Development Scenario

3.4. Competitive Pricing Analysis

3.5. Supplier - Distributor Analysis

Chapter 4. NEURODEGENERATIVE DISEASES DRUGS MARKET - Entry Scenario

4.1. Case Studies – Start-up/Thriving Companies

4.2. Regulatory Scenario - By Region

4.3 Customer Analysis

4.4. Porter's Five Force Model

       4.4.1. Bargaining Power of Suppliers

       4.4.2. Bargaining Powers of Customers

       4.4.3. Threat of New Entrants

       4.4.4. Rivalry among Existing Players

       4.4.5. Threat of Substitutes

Chapter 5. NEURODEGENERATIVE DISEASES DRUGS MARKET - Landscape

5.1. Value Chain Analysis – Key Stakeholders Impact Analysis

5.2. Market Drivers

5.3. Market Restraints/Challenges

5.4. Market Opportunities

Chapter 6. NEURODEGENERATIVE DISEASES DRUGS MARKET – By Drug class

6.1. Immunomodulator 

6.2. Interferons

6.3. Decarboxylase Inhibitors

6.4. Dopamine Agonists

6.5. Others

Chapter 7. NEURODEGENERATIVE DISEASES DRUGS MARKET – By Disease Indication

7.1. Multiple Sclerosis

7.2. Parkinson’s Disease

7.3. Alzheimer's Disease

7.4. Spinal Muscular Atrophy (SMA)

7.5. Others

Chapter 8. NEURODEGENERATIVE DISEASES DRUGS MARKET – By Route of Administration

8.1. Oral

8.2. Injection

8.3. Transdermal

Chapter 9. NEURODEGENERATIVE DISEASES DRUGS MARKET – By  End-User

9.1.Hospital Pharmacy

9.2. Retail Pharmacy

9.3. Online Pharmacy

Chapter 10. NEURODEGENERATIVE DISEASES DRUGS MARKET – By Region

10.1. North America

10.2. Europe

10.3.The Asia Pacific

10.4.Latin America

10.5. Middle-East and Africa

Chapter 11. NEURODEGENERATIVE DISEASES DRUGS MARKET– Company Profiles – (Overview, Product Portfolio, Financials, Developments)

11.1. Company 1

11.2. Company 2

11.3. Company 3

11.4. Company 4

11.5. Company 5

11.6. Company 6

11.7. Company 7

11.8. Company 8

11.9. Company 9

11.10. Company 10